ClinicalTrials.gg
RecruitingNCT07734857Updated Nov 10, 2026

Peripheral Blood Biomarkers and Response to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma

An observational study in Hepatocellular Carcinoma (HCC), sponsored by Shanghai Zhongshan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Shanghai Zhongshan Hospital · Observational

How we know · 2 judgments

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 10, 2026Now RecruitingFirst site in China+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 63 studies in Carcinoma, Hepatocellular by Shanghai Zhongshan Hospital — 27 open to participants now, 31 under way, 3 of them phase 3. Carcinoma, Hepatocellular · Shanghai Zhongshan Hospital.

Planned enrollment
18th of 21
100 · median 300
Started
2026
with 8 others
Observational
21 of 63
13 open now
Primary completion
2028-07
later than 25 of 30 live
Registered
56th of 63
by date

Among the 63 studies in Carcinoma, Hepatocellular by Shanghai Zhongshan Hospital, this one is the 18th largest by planned enrollment of the 21 observational ones that give a count, is one of 9 that started in 2026, is one of 21 observational ones, reaches primary completion later than 25 of the 30 other live ones, and was the 56th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

27 of the 63 studies in Carcinoma, Hepatocellular by Shanghai Zhongshan Hospital are open now, in 1 country. Recruiting first, the newest first:

21 more — sign in →

By country, each count listing its studies:

All 27 open studies →

Where they have run

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Carcinoma, Hepatocellular by Shanghai Zhongshan Hospital, or all of them as a file.
02

Study summary

This single-center prospective observational cohort study aims to evaluate the predictive value of peripheral blood-based biomarkers for treatment response in patients with hepatocellular carcinoma (HCC) receiving first-line atezolizumab plus bevacizumab (T+A) therapy. Residual peripheral blood samples obtained during routine clinical testing will be analyzed without additional blood draws. The study hypothesizes that baseline and longitudinal peripheral blood biomarkers are associated with treatment response and can be used to identify patients more likely to benefit from T+A therapy. Treatment response will be evaluated based on the best overall response (BOR) during treatment. The primary efficacy assessment will be performed according to RECIST 1.1, while modified RECIST (mRECIST) will be used as a supportive assessment. Predictive models based on peripheral blood biomarkers will be developed using RECIST 1.1-defined treatment response as the primary analysis, with mRECIST used for supportive and sensitivity analyses.

Read the detailed description

This is a single-center prospective observational cohort study designed to evaluate the predictive value of peripheral blood-based biomarkers for treatment response in patients with hepatocellular carcinoma (HCC) receiving first-line atezolizumab plus bevacizumab (T+A) therapy. T+A therapy has become a standard first-line treatment for advanced HCC; however, the objective response rate remains limited, and reliable non-invasive biomarkers for predicting treatment response are lacking. Consequently, accurate patient stratification and individualized prediction of treatment benefit remain challenging in clinical practice. We hypothesize that peripheral blood-based biomarkers, including serum-derived indicators such as secreted proteins, metabolites, and extracellular vesicle-related components, as well as peripheral blood cell-related markers, are associated with treatment response to T+A therapy and may help identify patients more likely to benefit from treatment. These biomarkers will be analyzed using approaches including proteomic and metabolomic analyses, extracellular vesicle-related assays, enzyme-linked immunosorbent assays (ELISAs), and peripheral blood cell-related analyses. Eligible patients scheduled to receive first-line T+A therapy will be consecutively enrolled at Zhongshan Hospital, Fudan University. When available, residual peripheral blood samples obtained during routine clinical testing will be collected at baseline, at routine treatment visits approximately every 3 weeks, and at the time of first documented disease progression. All participants will provide written informed consent for the use of residual biospecimens and clinical data. Participants may withdraw from the study at any time without affecting their subsequent medical care. Biospecimens and clinical data will be assigned unique study identification numbers and managed in a de-identified manner. Personally identifiable information will be stored separately with restricted access. Biospecimens and study data will be stored, managed, and destroyed in accordance with applicable institutional policies and ethical requirements. The study is expected to involve minimal additional risk because it does not require additional blood draws or alter standard clinical care. Treatment response will be evaluated based on the best overall response (BOR) during T+A therapy. The primary efficacy assessment will be performed according to RECIST 1.1, while modified RECIST (mRECIST) will be used as a supportive assessment for HCC-specific response evaluation. Participants will be categorized as responders if their BOR is complete response (CR) or partial response (PR), and as non-responders if their BOR is stable disease (SD) or progressive disease (PD). The primary objective is to compare baseline peripheral blood biomarker levels between responders and non-responders, as defined by RECIST 1.1, and to identify biomarkers associated with treatment benefit. Secondary objectives include evaluating longitudinal biomarker changes from baseline throughout T+A therapy, including fold changes and potential time windows associated with treatment response. Treatment response according to mRECIST will be evaluated as a supportive analysis, and sensitivity analyses based on mRECIST-defined response will be performed to assess the consistency and robustness of biomarker associations and predictive model performance. Predictive models will be developed using least absolute shrinkage and selection operator (LASSO)-based feature selection, with treatment response defined according to RECIST 1.1 as the primary endpoint. Model discrimination will be evaluated using receiver operating characteristic (ROC) curve analysis, including the area under the ROC curve (AUC), sensitivity, and specificity. Predictive performance based on mRECIST-defined response will be explored as a supportive analysis.

03

Conditions studied

  • Hepatocellular Carcinoma (HCC)
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with histologically or clinically confirmed unresectable or advanced HCC who are scheduled to receive first-line atezolizumab plus bevacizumab therapy at Zhongshan Hospital, Fudan University.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-80 years
  • Histologically or clinically confirmed unresectable or advanced HCC, classified according to the BCLC staging system
  • Planned to receive atezolizumab plus bevacizumab therapy, with no prior systemic therapy for unresectable or advanced HCC
  • At least one measurable target lesion with a longest diameter of ≥10 mm on CT or MRI according to 1.1, with assessment performed when applicable
  • Availability of baseline and follow-up clinical and radiological data
  • Willing and able to provide written

Exclusion criteria

Exclusion Criteria:

  • Presence of another active , except for malignancies that have been curatively treated and remain recurrence-free
  • Prior systemic treatment with or anti-angiogenic agents for unresectable or advanced HCC
  • Expected inability to complete the required clinical or radiological follow-up assessments
  • Severe comorbid conditions that may interfere with study participation
  • No qualified residual blood sample available for planned biomarker analyses because of insufficient volume, contamination, loss, or other sample-related issues
  • Any condition deemed unsuitable for participation by the investigator
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Interventions

  • OtherNo intervention (observational study)

    No intervention (observational study)

This study also gives AtezolizumabStudies of AtezolizumabAtezolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    Objective response rate, defined as the proportion of participants achieving CR or PR according to RECIST 1.1 based on the BOR during T+A therapy.

    Time frame: From treatment initiation up to 12 months.

Secondary outcomes

  1. Baseline Peripheral Blood Biomarker Concentrations

    Baseline concentrations of predefined peripheral blood biomarkers measured using ELISAs will be assessed before treatment initiation.

    Time frame: Baseline (within 7 days before treatment initiation).

  2. Change From Baseline in Peripheral Blood Biomarker Concentrations

    Changes from baseline in concentrations of predefined peripheral blood biomarkers measured using ELISAs will be assessed at serial treatment visits during T+A therapy.

    Time frame: Baseline and approximately every 3 weeks during treatment, up to 12 months.

  3. Progression-Free Survival

    Progression-free survival (PFS), defined as the time from treatment initiation to the first documented disease progression according to RECIST 1.1 or death from any cause, whichever occurs first.

    Time frame: From treatment initiation up to 12 months.

  4. Overall Survival

    Overall survival (OS), defined as the time from treatment initiation to death from any cause.

    Time frame: From treatment initiation up to 12 months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jul 2028, 22 months after the start.

Of 303 non-industry observational studies under Carcinoma, Hepatocellular, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 114. This study's planned 22 months is below that.

Counting every sponsor, half of 352 studies reached it within 51 months; a quarter within 32 and three quarters within 108.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Sep 2026, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2026
First posted
Jul 29, 2026
StartActual
Sep 1, 2026was Jul 2026
Primary completionEst.
Jul 10, 2028
CompletionEst.
Jul 30, 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 10, 2026
Sites
1 site added — first site in China
Show site
  • Zhongshan Hospital, Fudan University · Shanghai, China
Nov 10, 2026
Start date
Jul 10, 2026→Sep 1, 2026 (actual)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in China
    Show site
    • Zhongshan Hospital, Fudan University · Shanghai, China
    Start date Jul 10, 2026→Sep 1, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07734857
Responsible party
Sponsor
First posted
Jul 29, 2026
Start date
Sep 1, 2026
Primary completion
Jul 10, 2028 (estimated)
Completion
Jul 30, 2028 (estimated)
Last update
Nov 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion